Dive Brief: The Food and Drug Administration on Friday approved Novo Nordisk's newest treatment for obesity, a weekly injection called Wegovy. The Danish company followed up Monday with an announcement that it will set the list price at $1,297 a month, equivalent to its daily obesity drug Saxenda. Saxenda has been the most successful obesity drug launched in the past decade, earning sales of 5.6 billion Danish kroner, or about $918 million, in 2020. Wegovy is a similar drug to Saxenda, coming from class of drugs called glucagon-like peptide 1, or GLP-1, agonists, which are mainly used to control diabetes. In diabetes, Novo's GLP-1s are likely to face new pressure soon from rival Eli Lilly, which has developed a weekly combination shot called tirzepatide that has outperformed Novo's weekly drug. Novo is developing a similar drug, but it hasn't completed early stage trials.